Key Points Interested in Ocugen, Inc.? Here are five stocks we like better. Ocugen plans three late-stage retinal gene ...

Retinal diseases are at the forefront of a quiet revolution in the realm of ophthalmology. Gene therapy, once a distant dream, is now emerging as a beacon of hope for millions affected by these ...

A gene therapy that targets a form of retinitis pigmentosa showed a signal to improve retinal function for up to 3 years after treatment, according to a small clinical trial. The phase 2 SKYLINE trial ...

Inherited retinal degenerations (IRDs) are a group of genetic disorders that lead to progressive vision loss as the light-sensing cells of the eye—the photoreceptors—die due to mutations in genes ...

An experimental MeiraGTx gene therapy that has clinical data showing reversal of blindness in children born with a rare, inherited eye disorder is heading to Eli Lilly. According to the terms of the ...

Opus Genetics, Inc., a clinical-stage biotechnology company focusing on gene therapies for inherited retinal diseases, announced upcoming presentations at various scientific conferences in May 2025.

Gene therapy emerges as a transformative force in ophthalmology, offering renewed hope for patients with retinal diseases. This innovative approach targets both inherited and acquired conditions, ...

Bispecific antibody fares well against faricimab, two gene therapies extend treatment inte ...

Prior clinical successes with gene therapy for one of these diseases has raised hopes for patients and families affected by other such diseases, " says Editor-in-Chief Terence R. Flotte, MD, Celia and ...

Researchers from the NIHR Moorfields Biomedical Research Centre and University College London have found that gene therapy improved visual acuity and preserved retinal structure in young children with ...

Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease gene therapy. The candidate improved the structure and function of the ...